Executive Summary
Zi Medical plc has undergone a reverse takeover with Oxford Newtech, a company with a common aim to exploit the opportunity for consolidation in respect of such technology within the medical technology sector. Zi Medical's strategy is to advance concepts from prototype to market, in order to develop products for the growing global medical, clinical and pharmaceutical device and diagnostic markets. It focuses on products and systems that it considers will: *Expedite the drug development process; *Deliver drugs in a more efficient manner in the clinical setting; *Provide user friendly and improved diagnostic equipment; *Provide a fast path to revenue generation in point of care therapies in existing and emerging markets. Product Pipeline Portfolio : *\AD\ ambulatory syringe pump, fluid infusion devices containing new patented safety and design features. * \Red Eye\ intravenous drip monitor for gravity infusions targeted atd eveloping world markets. * \DrugPrint,\ designed to help develop and structure activity relationships in cardiovascular drug discovery programmes and to yield a reduction in the number of compounds that fail at the toxicology assessment stage and in early stage clinical development. This technology is potentially applicable to other areas, such as neuro-, hepato- and nephroptoxicity. * PathScore\, a fully validated, automated digital slide analyser platform. Clinical work to date has focused on developing the automatic detection and analysis of features required for diagnosis/prognosis and treatment of breast cancer.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
